Comparison of efficacy of oral Levamisole and Formoterol+Budesonide inhaler with standard treatment of Corona infection.

Evaluation of efficacy of pharmacotherapy treatment of COVID- 19 infection using oral Levamisole and Formoterol+Budesonide inhaler and comparison of this treatment protocol with standard national treatment of the disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200324046852N1

Enrollment

Registered

2020-04-05

Start date

2020-04-01

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corona virus infection. COVID-19, confirmed by laboratory testing

Interventions

Intervention 1: Intervention group:In this group along with the standard drugs according to the national guideline of treatment for COVID-19, patients will take Levamisole 50 mg TDS for 3-7 days, made

160/4.5 and 320/9 mcg respectively. Decision about the used strength and dose of drug depends on the situation of the disease and will be made by physician. Intervention 2: Control group: This group j

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COVID-19 positive patients with positive, PCR and chest CT scan

Exclusion criteria

Exclusion criteria: Patients with sever respiratory problems including patients with:1. Spo2<60%2. Severe respiratory distress3. Heamodynamic instabilitty 4. Acid base disturbance 5. Severe Anemia Patients with hepatic diseases Patients with Nervous system diseases

Design outcomes

Primary

Measure	Time frame
Response to treatment in Lymphocytes count. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Response to treatment for COVID-19 specific PCR test. Timepoint: Days 0-3-7. Method of measurement: Using PCR apparatus.;Response to treatment in O2 level and CO2 level in ABG or VBG test. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Chest CT-Scan response to treatment including dispersion size of Ground Glass area, bronchitis and consolidation. Timepoint: Days 0-3-7. Method of measurement: CT scan apparatus.	—

Measure

Time frame

Response to treatment in Lymphocytes count. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Response to treatment for COVID-19 specific PCR test. Timepoint: Days 0-3-7. Method of measurement: Using PCR apparatus.;Response to treatment in O2 level and CO2 level in ABG or VBG test. Timepoint: Daily. Method of measurement: By apparatus in diagnostic lab.;Chest CT-Scan response to treatment including dispersion size of Ground Glass area, bronchitis and consolidation. Timepoint: Days 0-3-7. Method of measurement: CT scan apparatus.

—

Secondary

Measure	Time frame
Blood pressure response to treatment. Timepoint: daily. Method of measurement: By Sphygmomanometer.;Creatinine level during intervention. Timepoint: Daily. Method of measurement: By apparatus in diagnostic labs.;Level of CRP ( C reactive protein) in response to intervention. Timepoint: Daily. Method of measurement: By apparatus in diagnostic labs.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Siamack Afazeli

Fasa University of Medical Sciences

dr.afazeli@gmail.com+98 21 6647 5335

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026